From Medscape Oncology

Coverage from the

American Society of Hematology (ASH) 2022 Annual Meeting

December 10 - 13, 2022; New Orleans, Louisiana and Virtual/Online

December 10 - 13, 2022 New Orleans, Louisiana and Virtual/Online

ASH 2022 'Astonishing' Results: Skip Salvage Chemo, Go Straight to HSCT Investigators said they were astonished by the results they saw when patients with refractory acute myeloid leukemia went straight to an allogeneic stem cell transplant.
Medscape Medical News, December 11, 2022
ASH 2022 Worldwide Efforts Needed to Close Regional HSCT Utilization Gap Although hematopoietic stem cell transplants (HSCT) offer a cure for acute myeloid leukemia, in some countries only 5% of patients are offered this option.
Medscape Medical News, December 10, 2022
ASH 2022 ASH 2022: New Clinical Data Challenge Long-held Assumptions Abstracts will include both practice-changing trial results and data showing that sometimes doing less can be better for both for patients and for clinical practice.
Medscape Medical News, December 5, 2022

Conference News

ASH 2022 The Latest on COVID-19, Immunity, and Thrombosis Risk
MDedge News, December 23, 2022
ASH 2022 Formula-Fed Extreme Preemies Need More Iron: Study
MDedge News, December 19, 2022
ASH 2022 Beta-thalassemia: Benefits of Gene Therapy Outweigh Costs
MDedge News, December 15, 2022
ASH 2022 ITP: Biologic Beat Placebo, but Few Patients Improved
MDedge News, December 15, 2022
ASH 2022 Steep Price for Surviving Childhood Lymphoma: Epigenetic Aging
Medscape Medical News, December 13, 2022
ASH 2022 MCL: Ibrutinib Could Become the 'New Standard'
MDedge News, December 13, 2022
ASH 2022 Alloantibody Data Exchange Would Save Lives, Reduce Costs
Medscape Medical News, December 13, 2022
ASH 2022 High Response Rates With Talquetamab in Advanced Myeloma
Medscape Medical News, December 12, 2022

ASH 2022 High Price for Gene Therapy ― But Cost-Effective in Sickle Cell
Medscape Medical News, December 12, 2022
ASH 2022 No Need for Strict Neutropenic Diet After HSCT
MDedge News, December 12, 2022
ASH 2022 High-Dose MTX Does Not Reduce CNS Relapse in Pediatric ALL
Medscape Medical News, December 11, 2022
ASH 2022 'Astonishing' Results: Skip Salvage Chemo, Go Straight to HSCT
Medscape Medical News, December 11, 2022
ASH 2022 For Minorities With PE: Less Advanced Treatment, More Mortality
MDedge News, December 10, 2022
ASH 2022 Poorly Matched Stem Cell Transplants Linked to Ancestry
MDedge News, December 10, 2022
ASH 2022 Worldwide Efforts Needed to Close Regional HSCT Utilization Gap
Medscape Medical News, December 10, 2022
ASH 2022 ASH 2022: New Clinical Data Challenge Long-held Assumptions
Medscape Medical News, December 5, 2022

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

Chronic Lymphocytic Leukemia Highlights From ASH 2022
Jan Burger, MD, PhD
Breakthroughs in Mantle Cell Lymphoma From ASH 2022
Peter Martin, MD
Highlights in Multiple Myeloma From ASH 2022
Joseph Mikhael, MD
Key Data in Non-Hodgkin Lymphoma From ASH 2022
Michael R. Bishop, MD
Advances in CAR-T Cell Therapy From ASH 2022
Michael R. Bishop, MD

Popular News from ASH 2021

New Approaches to Hemophilia Treatment: 'Our Cup Runneth Over' New approaches to treating hemophilia may soon replace the decades-old approach of using factor concentrates to control bleeding in patients with hemophilia A and hemophilia B.
Medscape Medical News, Dec 22, 2021
Aggressive Supportive Treatment for COVID-19 in Leukemia and MDS New findings provide preliminary evidence to use aggressive supportive treatment of COVID-19 in patients with acute leukemias and myelodysplastic syndromes.
Medscape Medical News, Dec 12, 2021
'Remarkable' Results With CAR T Cells Could Make Chemo Obsolete Chemotherapy, the decades-old approach to second-line therapy for relapsed/refractory large B cell lymphomas, may soon be obsolete, investigators say.
Medscape Medical News, Dec 11, 2021

Previous Coverage